PI3K/p110β-specific inhibitors in castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 195-199, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-812787
ABSTRACT
Advanced prostate cancer, especially at the castration-resistant stage, remains incurable clinically and, therefore, urgently requires new therapeutics for the patients. PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression. It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer. Several p110-specific inhibitors have been reported recently and two of them, GSK2636771 and AZD8186, are being tested in clinical trials.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Morfolinas
/
Cromonas
/
Fosfatidilinositol 3-Quinases
/
Usos Terapêuticos
/
Inibidores de Proteínas Quinases
/
Tratamento Farmacológico
/
Neoplasias de Próstata Resistentes à Castração
/
Inibidores de Fosfoinositídeo-3 Quinase
/
Imidazóis
/
Compostos de Anilina
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS